Drug Trial Radar · NCT06308653
Psilocybin for Major Depressive Disorder (MDD)
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
238
Actual
Start
Mar 13, 2024
Primary completion
Jan 5, 2026
Study completion Jan 30, 2027
Sponsor
- Lead sponsor
- Usona InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between groups in change in depressive symptoms from Baseline to Day 43 post-dose, and to characterize the durability of initial treatment effect and subsequent response to optional Psilocybin 25 mg re-administration(s) during the 1-year Follow-up Period.
Conditions
- Depressive Disorder, Major
Interventions
Psilocybin 25 mgDrug
The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Psilocybin.
Inactive PlaceboDrug
The inactive placebo is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Microcrystalline Cellulose (MCC). The MCC is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use.
Psilocybin 5 mgDrug
The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active comparator is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 5 mg of Psilocybin.
Psychosocial SupportBehavioral
Psychosocial Support, including psychoeducation, begins after the Double-blind Period and continues throughout the 1-year Follow-up Period in order to enhance participant safety and maximize retention for the entire trial duration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in central rater Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline to Trial Day 43Time frame: From Trial Baseline to Trial Day 43
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama Clinical Research Unit
Birmingham, Alabama
Preferred Research Partners-NWA, LLC
Fayetteville, Arkansas
Preferred Research Partners, Inc.
Little Rock, Arkansas
Kadima Neuropsychiatry Institute
La Jolla, California
West LA VA Medical Center - Mental Health Department
Los Angeles, California
Pacific Neuroscience Institute (PNI) at Saint John's Physician Partners
Santa Monica, California
Psychedelic Science Institute
Santa Monica, California
Mountain View Clinical Research
Denver, Colorado
Connecticut Mental Health Center, Yale University
New Haven, Connecticut
Clinical Neuroscience Solutions Inc.
Jacksonville, Florida
Innovative Clinical Research, Inc.
Lauderhill, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Emory University
Atlanta, Georgia
CenExel iResearch, LLC
Decatur, Georgia
Great Lakes Clinical Trials
Chicago, Illinois
Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness Research
Baltimore, Maryland
Sunstone Medical PC
Rockville, Maryland
Washington University School of Medicine
St Louis, Missouri
VA Nebraska Western Iowa Health Care System
Omaha, Nebraska
Global Medical Institutes, LLC; Princeton Medical Institute
Princeton, New Jersey
University of New Mexico (UNM) Interdisciplinary Substance Use and Brain Injury (ISUBI) Center
Albuquerque, New Mexico
NYU Clinical & Translational Science Institute
New York, New York
Bronx Veterans Research Foundation at the James J. Peters VAMC
The Bronx, New York
AIM Trials, LLC
Plano, Texas
Clinical Trials of Texas, LLC
San Antonio, Texas
Cedar Clinical Research
Draper, Utah
Cedar Clinical Research, Inc.
Murray, Utah
Seattle Neuropsychiatric Treatment Center
Bellevue, Washington
VA Portland Health Care System
Vancouver, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.